PROMO.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 saus. 2024 @ 18:21):

Stats
Dzisiejszy wolumen	1.12M
Średni wolumen	2.06M
Kapitalizacja rynkowa	293.55M
EPS	SEK-0.0643 ( 2023-09-30 )
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.314
ATR14	SEK5.16 (36.49%)

Wolumen Korelacja

Długi: -0.10 (neutral)

Krótki: 0.27 (neutral)

Signal:(45.746) Neutral

Promore Pharma AB (publ) Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Promore Pharma AB (publ) Korelacja - Waluta/Towar

0.10
( neutral )

0.53
( weak )

-0.02
( neutral )

0.12
( neutral )

-0.67
( moderate negative )

-0.57
( weak negative )

Promore Pharma AB (publ) Finanse

Annual	2022
Przychody:	SEK99 000.00
Zysk brutto:	SEK-15.85M (-16 005.05 %)
EPS:	SEK-0.440

FY	2022
Przychody:	SEK99 000.00
Zysk brutto:	SEK-15.85M (-16 005.05 %)
EPS:	SEK-0.440

FY	2021
Przychody:	SEK417 000
Zysk brutto:	SEK-14.90M (-3 571.94 %)
EPS:	SEK-0.561

FY	2020
Przychody:	SEK3 000.00
Zysk brutto:	SEK-18.20M (-606 733.33 %)
EPS:	SEK-0.796

Financial Reports:

No articles found.

Promore Pharma AB (publ)

Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers, stimulate the healing of chronic wounds, and for the treatment of diabetic foot ulcers. It entered into a cooperation agreement with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is headquartered in Solna, Sweden.